Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that Telomir-Zn, its lead small-molecule therapeutic, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The findings, published in the Journal of Oncology Research and Therapy, provide the scientific foundation for advancing Telomir-Zn toward a planned Phase 1/2 clinical trial in TNBC under the company's active Investigational New Drug (IND) application.
The study revealed that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, a mechanism that selectively kills iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. In a prostate cancer model, the compound reactivated tumor-suppressor genes, further underscoring its potential in epigenetic regulation.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, in BT-549 xenografts, combining Telomir-Zn with paclitaxel produced significantly greater tumor reduction than either treatment alone, suggesting a potential synergistic effect. However, MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity to the therapy.
These results are particularly significant for TNBC, a subtype of breast cancer that is notoriously aggressive and has limited treatment options. TNBC accounts for approximately 10-15% of all breast cancers and is characterized by the absence of estrogen, progesterone, and HER2 receptors, making it unresponsive to hormonal therapies and HER2-targeted agents. The standard of care typically involves chemotherapy, but relapse rates are high, and metastatic disease has a poor prognosis. Telomir-Zn's mechanism of action, targeting iron and copper metabolism, offers a novel approach that could potentially be integrated into existing treatment regimens.
For the broader oncology field, this research highlights the growing importance of metal homeostasis and epigenetic regulation as therapeutic targets. By selectively depleting intracellular iron, Telomir-Zn may offer a way to exploit the metabolic vulnerabilities of cancer cells, potentially leading to more effective and less toxic treatments. The data also underscore the need for biomarker-driven patient selection, as the differential response in xenograft models suggests that some tumors may be inherently resistant to this approach.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The publication of these peer-reviewed data marks a key milestone in advancing the program toward clinical testing.
For more information about Telomir Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TELO. To view the full press release, visit https://ibn.fm/mv3hn.
